AXNX News and Press, Axonics Modulation Technologies Inc. From 02/24/22

Axonics Modulation Technologies press release (NASDAQ:AXNX): Q4 GAAP EPS of -$0.34 beats by $0.02. Revenue of $53.1M (+52.6% Y/Y) beats by $2.58M. For further details see: Axonics Modulation Technologies GAAP EPS of -$0.34 beats by $0.02, revenue of $53.1M beats by $2.58M

Total revenue of $53.1 million in 4Q21, an increase of 53% year over year Fiscal year 2022 revenue outlook of $234 million, an increase of 30% year over year Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing nove...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24,...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the SVB Leerink Virtual Healthcare Conference on February 17, 2022. Axonics is s...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today highlighted the publication of a new study that provides updated estimates of urinary incontinence (UI) preva...

Quarterly revenue exceeds $50 million for the first time Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited net reven...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Raymond W. Cohen, chief executive officer of Axonics, has been awarded the 2021 Lifetime Entre...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 1 on the Deloitte Technology Fast 500™ , a ranking of the 500 fastest-grow...

Deloitte Unveils 2021 North America Technology Fast 500 Rankings California-based global medical technology company claims top spot in 27th annual ranking of fastest-growing businesses PR Newswire SAN FRANCISCO , Nov. 17, 2021 /PRNewswire/ -- Deloitte today r...

Axonics, Inc. (AXNX) Q3 2021 Earnings Conference Call November 4, 2021 16:30 ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer & Director Dan Dearen - President & Chief Financial Officer Conference Call Participants A...